A new report published in The Lancet Diabetes & Endocrinology challenges the conventional definition of obesity, and urges a shift from the reliance on Body Mass Index (BMI) to a more nuanced approach. This is supported by over 50 global medical experts. The report also recommends splitting the term "obesity" into two categories: "Clinical obesity" and "Pre-clinical obesity". This aims to improve diagnosis and treatment for over a billion people worldwide living with obesity.

Clinically Obese

This applies to individuals whose obesity has progressed to a disease state, manifesting in organ damage, heart disease, type 2 diabetes, or other health complications. These individuals could also experience symptoms like breathlessness, joint pain, or impaired daily functioning. Treatment also involves medical interventions, including weight-loss medications or surgery.

Pre-Clinic Obese

Whereas the term "pre-clinic obese" refers to those who are overweight but not yet exhibiting health issues. While they may be at risk of developing obesity-related conditions, their organ function and overall health remain intact. What they need is preventive care, which includes dietary guidance, counselling, and regular monitoring to avoid and reduce future health risks.

What does the study say?

The study, led by Professor Francesco Rubino from King's College London emphasizes that obesity is not one-size-fits-all condition. This means it should rather be treated as a spectrum as some individuals maintain normal organ function despite being classified as obese. There are others who may face severe health complications too. However, the current method of calculating obesity based on BMI often leads to misdiagnosis or inadequate care.

The report also states that BMI, while is useful for analyzing population trends, is a flawed unit of measuring individual health. Therefore, there is a need to redefine obesity, and healthcare professionals can provide more precise care by distinguishing those who need immediate medical intervention and those who require preventive strategies.

Limitations of BMI, Why It Falls Short?

BMI is used to classify individuals as underweight, healthy weight, overweight, or obese based on their height and weight. It is calculated by dividing weight in kilograms by health in meters squared. However, there are reasons while it falls short.

•Muscle vs Fat: Athletes or muscular individuals often have high BMIs despite the low body fat

•Fat Distribution: BMI does not measure fat around the waist or organs, which could be more dangerous to one's health.

•Individual Health Variation: It also overlooks the specific health conditions such as heart diseases or diabetes, or any other, while evaluating a person's category in terms of weight.

ALSO READ: Is It Time To Say Goodbye To BMI?

Scope Of Study

By redefining obesity, the study could transform the approach to diagnosis and treatment. It can focus on individual health risks rather than BMI alone. Healthcare providers can also offer tailored care. This also will ensure hat weight-loss medications like Wegovy or Mounjaro are prescribed only to those who genuinely require it.

As per Professor Louise Baur from the University of Sydney, a Children's obesity expert said that this redefinition allows both adults and children to receive more appropriate care while reducing over-diagnosis and unnecessary treatments.

Six unvaccinated people, including children, have died from measles in the US this year. As of October 8, the country had reported 4,080 confirmed cases, according to the Centers for Disease Control and Prevention (CDC).

Measles spreads easily through the air and can remain infectious for up to two hours. Symptoms include high fever, cough, runny nose, red, watery eyes, and a rash that typically starts on the face. Infected people can spread the virus before the rash appears.

Two doses of the measles, mumps, and rubella (MMR) vaccine are approximately 97% effective against measles and remain the best protection against the disease and its complications.

Measles Can Cause Complications Years Later

Also read: Sixth Measles-Associated Death Reported In Pennsylvania As Cases Cross 1,100

Measles also causes pneumonia, brain inflammation, and death. Some complications emerge weeks or years after the initial infection.

Three serious consequences are acute disseminated encephalomyelitis (ADEM), immune amnesia, and subacute sclerosing panencephalitis (SSPE).

According to the CDC, one to three out of every 1,000 children with measles die from respiratory and neurological complications.

ADEM: When the Immune System Attacks the Brain

An 18-year-old from Mifflin County, Pennsylvania, died from acute disseminated encephalomyelitis (ADEM), reported as the state's fourth measles-associated death this year.

ADEM causes inflammation in the brain and spinal cord when the immune system mistakenly attacks nervous system tissue. It can develop weeks after infections such as measles or influenza.

Symptoms include weakness, confusion, vision problems, and seizures. Severe cases can be fatal.

ADEM occurs in approximately one out of every 1,000 measles cases. Treatment may include steroids, intravenous immunoglobulin, and plasma exchange.

Most patients recover, but lasting problems can include motor weakness, cognitive impairment, seizures, and vision loss. In a 2022 study of 77 children with moderate to severe ADEM, nearly a quarter had persistent health issues.

Immune Amnesia: Measles Can Erase Immune Memory

Read More: Measles Cases Are Rising in US—Who Should Get A Booster Shot?

Measles can destroy immune cells that remember previously encountered pathogens, weakening protection built through past infections and vaccinations. This is known as immune amnesia.

“Immune amnesia basically destroys your immune system,” said Dr. Stephen J. Elledge, professor of genetics and medicine at Harvard Medical School. “It infects and kills the cells that store immune memories — plasma cells, B cells, and T cells. It’s like burning down a library full of immunological knowledge.”

A 2019 study published in Science, co-authored by Elledge, found that measles could erase up to 73% of a person's antibody repertoire.

This loss can leave people vulnerable to infections their immune systems had previously learned to fight. Research published in 2015 suggested that rebuilding immune protection can take two to three years.

SSPE: A Fatal Disease That Can Emerge Years Later

Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological disease caused by a persistent measles virus infection in the central nervous system.

SSPE is "the most enigmatic and terrifying consequence of measles", Andrew Pavia, MD, a pediatric infectious disease epidemiologist at the University of Utah, told CIDRAP News.

Symptoms may appear seven to 10 years after measles, even in people who initially recover. Early signs include personality changes, mood swings, and headaches. The disease can progress to involuntary movements, seizures, vision loss, cognitive decline, coma, and death.

There is no known cure, and SSPE is ultimately fatal.

Infants Face a Higher SSPE Risk

Children who contract measles during infancy face a particularly high risk of SSPE.

The CDC estimated that seven to 11 out of every 100,000 people infected during the US measles resurgence of 1989–1991 were at risk of developing the disease.

A 2016 review of California health records estimated that SSPE occurred in approximately one out of every 609 children who contracted measles before 12 months of age.

A child in Los Angeles died of SSPE last year after contracting measles as an infant, before becoming eligible for the MMR vaccine. In the United States, the first dose is generally recommended at 12 to 15 months.

With measles cases continuing to rise, Pavia warned that SSPE "is a potential time bomb."

The increasing popularity of GLP-1 medications is making its way onto college campuses, where young women face growing pressure to meet ideals of thinness and beauty.

Media reports suggest that the use of GLP-1 drugs, including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), is rising among young women, including those with normal BMIs, seeking to achieve a thinner appearance.

Originally developed to treat type 2 diabetes, with some also approved for weight management, these medications can be highly effective but require a prescription and appropriate medical monitoring. Using them without a medical indication may expose people to unnecessary health risks, an expert warned.

Jay Campbell, a longevity and peptide expert and bestselling author, said

that while these drugs were developed to address metabolic conditions, they have been “hijacked as a cosmetic shortcut.”

“For someone who's metabolically dysregulated, they are a genuine medical intervention,” he told Fox News Digital. “But to a 20-year-old sorority member with a normal BMI, they look like an aesthetic hack in a syringe.”

GLP-1 Drugs Gain Attention Among College Girls

Also read: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth

A 2024 analysis published in JAMA found that 162,439 young adults ages 18 to 25 received at least one dispensed GLP-1 prescription in 2023.

Women accounted for 76.4% of these patients, although the analysis included medications prescribed for both diabetes and weight management.

Separately, the 2025 Monitoring the Future survey found that 2% of students in grades 8, 10 and 12 reported using a prescription GLP-1 medication, while another 2% said they had used one without a prescription.

Sororities can amplify pressure to maintain a certain appearance, with social media and comparisons among members potentially encouraging interest in GLP-1 drugs. Campbell said rapid, visible weight loss can quickly become a talking point within sorority houses, prompting other young women to consider the drugs as a shortcut to achieving a thinner look, including those with normal BMIs.

Risks of Using GLP-1 Drugs for Cosmetic Weight Loss

College-aged women may already be vulnerable to body-image pressures, Campbell noted, and social media can intensify those concerns.

GLP-1 medications can offer substantial benefits to eligible patients. In clinical studies of people taking these medications for obesity, fat mass generally accounts for more of the weight lost than lean mass, Campbell pointed out.

“The peptide isn't catabolic by itself – the real risk is that a healthy 20-year-old who isn't obese has far less metabolic and muscular reserve to lose from in the first place.”

When a young woman loses weight rapidly without consuming enough protein or doing resistance training, she may lose a greater proportion of lean mass, Campbell warned. Rapid weight loss can also contribute to facial and body changes sometimes referred to as “Ozempic face” and “Ozempic body.”

Read More: WHO Cautions Against GLP-1s As First-Line Treatment For Childhood Obesity, Prioritises Lifestyle Changes

5 Things To Know Before Using GLP-1 Drugs

1. Check if you need them: Consult a doctor to determine whether GLP-1 treatment is medically appropriate.
2. Protect muscle mass: Eat enough protein and include resistance training to help preserve muscle during weight loss.
3. Understand pregnancy risks: Semaglutide labeling advises stopping Wegovy at least two months before a planned pregnancy. Tirzepatide can reduce oral contraceptive effectiveness for four weeks after starting treatment and after each dose increase.
4. Monitor mental health: Discuss any history of eating disorders, anxiety or depression with your prescriber and report worsening symptoms.
5. Consider long-term safety: Discuss potential risks, side effects and ongoing monitoring with a qualified doctor before starting treatment.

An unexplained blood clot could sometimes be the first warning sign of underlying cancer. In such cases, doctors investigate beyond the immediate causes of thrombosis.

While blood clots are mostly caused after surgery, prolonged immobility and other risk factors, a clot that develops without a known trigger may need a closer look, especially in older adults or patients with other certain concerning symptoms.

On World Thrombosis Day, observed on October 13, experts talk about the importance of recognising unusual clotting patterns and investigating underlying conditions without subjecting every patient to unnecessary tests.

“Sometimes an unexplained blood clot is the first clinical sign of an underlying cancer,” Dr Rahul Bhargava, Principal Director and Chief of Hematology, Hemato Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute (FMRI), Gurugram told HealthandMe.

Can Cancer Trigger Blood Clots?

Cancer can interfere with the body's normal clotting mechanisms. Dr Bhargava explained, “Some tumors are able to activate the body’s clotting system by releasing substances such as tissue factor, which stimulates the production of thrombin and fibrin, the proteins involved in clot formation.”

He added that inflammation related to cancer and changes to blood vessels contribute to hypercoagulability, a condition in which the blood has an increased tendency to clot. In some patients, a tumour may also compress blood vessels, slowing blood flow. Cancer treatments, including surgery and certain chemotherapy drugs, can further increase the risk.

Dr Narendra Agrawal, Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute and Research Centre, explained to us that the body's natural anticoagulants help maintain blood in a liquid state. When these protective mechanisms are deficient, whether due to congenital mutations or other reasons, the risk of clotting can increase.

“When cancer is present in the body, it acts as a major driver of abnormal clotting within the vessels, making an unprovoked clot a critical clinical indicator that a malignancy may be forming,” he said.

However, an unexplained clot does not necessarily mean a person has cancer. Doctors must evaluate the patient's symptoms, medical history and other risk factors before deciding whether investigations are warranted.

Also read: Menopause Abruptly Shifts Bones, Liver And Blood Fats, Study Finds

Key Warning Signs

The absence of a clear trigger is a red flag that should not be ignored. Doctors typically look for common causes like recent surgery, trauma, prolonged immobility or long-distance travel before investigating other possibilities.

Dr Bhargava said concern increases when thrombosis occurs without an identifiable cause, particularly in older adults, or when a clot recurs despite adequate treatment. Other warning signs include unexplained weight loss, chronic fatigue, poor appetite, bleeding and changes in bowel movements.

“There is no particular symptom which will allow to distinguish cancer-associated thrombosis from others,” he cautioned, emphasising the need for a comprehensive clinical assessment rather than assuming that every unexplained clot indicates malignancy.

Dr Agrawal also highlighted specific findings that may prompt further investigation. “We suspect an underlying cancer when we encounter specific red flags,” he said, referring to unprovoked clots in older patients and physical findings like lumps, non-healing ulcers, recurring abdominal pain or blood in the stool.

Abnormal blood counts can provide additional clues. Changes in haemoglobin, white blood cell counts or platelet levels may lead doctors to investigate possible blood-related cancers or other underlying conditions.

Also read: 'Humanity Can Still Act': Lancet Warns Of 17 Global Health Threats By 2100

Cancers Linked With Unexplained Blood Clots

Certain cancers come with a greater risk of venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).

“Certain cancers that predispose one to venous thromboembolism include pancreatic, lung, stomach, colorectal and ovarian cancers. Others include some forms of blood cancers,” Dr Bhargava said.

He explained that the risk varies according to the type and stage of cancer and the treatment involved. In some patients, an unprovoked clot may develop before the cancer itself is diagnosed.

The location of the clot can also influence how symptoms appear. DVT commonly affects the deep veins of the legs, causing swelling, pain and tenderness. When a clot travels to the lungs and causes a pulmonary embolism, symptoms may include chest pain and breathlessness.

Dr Agrawal said that clots in abdominal veins may cause abdominal pain, liver dysfunction, an enlarged spleen or intestinal bleeding. Clots affecting blood vessels in the brain or central nervous system may produce neurological symptoms, including paralysis. However, the location of a clot alone cannot prove if cancer is present.

Also read: High BP in Pregnancy Linked to 42,000 Maternal Deaths, 500,000+ Stillbirths, Newborn Deaths: WHO

What Investigations Are Recommended?

Doctors generally begin with a detailed medical history, physical examination and blood tests. These may include a complete blood count and assessments of kidney and liver function. Further testing depends on the clinical findings. Imaging or endoscopy may be recommended when symptoms, examination findings or blood abnormalities raise suspicion of an underlying malignancy.

Dr Bhargava cautioned against automatically subjecting every patient with unexplained thrombosis to extensive testing. “It is not always necessary to perform extensive imaging of the whole body or tumour marker testing in every patient with a clot that is unexplained and does not have any other worrying signs,” he said.

The aim is to identify cancers that warrant further investigation while avoiding unnecessary radiation exposure and incidental findings.

Dr Agrawal said doctors may use CT scans to look for hidden tumours, with MRI or PET scans considered for specific cancer evaluations. The extent of testing depends on factors such as the patient's age, clinical presentation, blood counts and physical examination findings.

When a patient has both cancer and thrombosis, doctors must manage the clot while navigating cancer treatment and the patient's risk of bleeding. “Anticoagulants are usually administered to prevent the expansion of the existing clot and the occurrence of other clots,” Dr Bhargava said.

The choice of medication, including a direct oral anticoagulant or low molecular weight heparin, depends on the patient's condition. Factors include kidney function, the possibility of gastrointestinal or urinary bleeding, drug interactions and the type of cancer treatment being administered.

Dr Bhargava explained that doctors must also consider platelet counts, planned or recent surgery, chemotherapy-related complications and active bleeding. The duration of anticoagulation is individualised and may extend beyond three to six months while the cancer and its treatment continue to pose a risk.